{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:43:34Z","timestamp":1768779814466,"version":"3.49.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1013","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The risk of hyperkalaemia in patients with heart failure has increased in the past few years together with the evolution of pharmacological treatment for these patients. This significant change has been associated with the introduction of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. High potassium concentrations in heart failure could lead to life threatening events, and therefore should be taken seriously. In this review we summarise the information about potassium homeostasis in heart failure and the current risk of developing potentially serious hyperkalaemia, particularly in association with the use of aldosterone antagonists.<\/jats:p>","DOI":"10.1136\/pgmj.2008.072058","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T12:33:13Z","timestamp":1268829193000},"page":"136-142","source":"Crossref","is-referenced-by-count":20,"title":["Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism"],"prefix":"10.1093","volume":"86","author":[{"given":"Rosana","family":"Poggio","sequence":"first","affiliation":[{"name":"Heart Failure and Heart Transplant Program, Department of Cardiology, FLENI , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo O","family":"Grancelli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, FLENI , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago G","family":"Miriuka","sequence":"additional","affiliation":[{"name":"Heart Failure and Heart Transplant Program, Department of Cardiology, FLENI , Buenos Aires , Argentina"},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET) , Buenos Aires , Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,3,17]]},"reference":[{"key":"2023041908483445000_b1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10741-005-2342-4","article-title":"Aldosterone and heart failure: the rest of the story","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2023041908483445000_b2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0140-6736(76)90965-X","article-title":"Effect of long-term diuretic treatment on body-potassium in heart-disease","volume":"2","author":"Davidson","year":"1976","journal-title":"Lancet"},{"key":"2023041908483445000_b3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"2023041908483445000_b4","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"2023041908483445000_b5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"2023041908483445000_b6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2005.07.067","article-title":"Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?","volume":"47","author":"Schrier","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2023041908483445000_b7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2023041908483445000_b8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041908483445000_b9","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0002-9149(93)90238-8","article-title":"Aldosterone and antialdosterone therapy in congestive heart failure","volume":"71","author":"Weber","year":"1993","journal-title":"Am J Cardiol"},{"key":"2023041908483445000_b10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2023041908483445000_b11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/0002-8703(70)90107-9","article-title":"Combinations of diuretics in the treatment of edema","volume":"80","author":"Leiter","year":"1970","journal-title":"Am Heart J"},{"key":"2023041908483445000_b12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cardfail.2006.01.013","article-title":"Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis","volume":"12","author":"Baliga","year":"2006","journal-title":"J Card Fail"},{"key":"2023041908483445000_b13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"2023041908483445000_b14","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"2023041908483445000_b15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2023041908483445000_b16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2006.05.030","article-title":"Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials","volume":"152","author":"deDenue","year":"2008","journal-title":"Am Heart J"},{"key":"2023041908483445000_b17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1006\/jmcc.2002.2088","article-title":"Molecular mechanisms of myocardial remodeling. The role of aldosterone","volume":"34","author":"Delcayre","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"2023041908483445000_b18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"2023041908483445000_b19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2023041908483445000_b20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cardfail.2006.11.016","article-title":"The effect of spironolactone use on heart failure mortality: a population-based study","volume":"13","author":"Ouzounian","year":"2007","journal-title":"J Card Fail"},{"key":"2023041908483445000_b21","doi-asserted-by":"crossref","first-page":"36K","DOI":"10.1016\/0002-9149(90)91276-C","article-title":"Spironolactone versus nifedipine in essential hypertension","volume":"65","author":"Henry","year":"1990","journal-title":"Am J Cardiol"},{"issue":"11 Pt 1","key":"2023041908483445000_b22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"issue":"4 Pt 1","key":"2023041908483445000_b23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","article-title":"The role of spironolactone in the treatment of patients with refractory hypertension","volume":"15","author":"Ouzan","year":"2002","journal-title":"Am J Hypertens"},{"key":"2023041908483445000_b24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041908483445000_b25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"},{"key":"2023041908483445000_b26","doi-asserted-by":"crossref","first-page":"29A","DOI":"10.1016\/0002-9149(93)90242-5","article-title":"Captopril and spironolactone therapy for refractory congestive heart failure","volume":"71","author":"Dahlstrom","year":"1993","journal-title":"Am J Cardiol"},{"key":"2023041908483445000_b27","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfg295","article-title":"Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone","volume":"18","author":"Cruz","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2023041908483445000_b28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2023041908483445000_b29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","article-title":"How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?","volume":"10","author":"Svensson","year":"2004","journal-title":"J Card Fail"},{"key":"2023041908483445000_b30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2125.2004.02187.x","article-title":"Tolerability of spironolactone in patients with chronic heart failure \u2013 a cautionary message","volume":"58","author":"Witham","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2023041908483445000_b31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","article-title":"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure","volume":"148","author":"Tamirisa","year":"2004","journal-title":"Am Heart J"},{"key":"2023041908483445000_b32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2710.2005.00638.x","article-title":"Clinical factors associated with hyperkalemia in patients with congestive heart failure","volume":"30","author":"Ramadan","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"2023041908483445000_b33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2005.00694.x","article-title":"Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil","volume":"30","author":"Saito","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"2023041908483445000_b34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023041908483445000_b35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0002-9149(02)02581-X","article-title":"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease","volume":"90","author":"Obialo","year":"2002","journal-title":"Am J Cardiol"},{"key":"2023041908483445000_b36","first-page":"208","article-title":"Risk calculation for hyperkalaemia in heart failure patients","volume":"65","author":"Vereijken","year":"2007","journal-title":"Neth J Med"},{"key":"2023041908483445000_b37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cardfail.2006.01.003","article-title":"Appropriateness of spironolactone prescribing in heart failure patients: a population-based study","volume":"12","author":"Ko","year":"2006","journal-title":"J Card Fail"},{"key":"2023041908483445000_b38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.104.527549","article-title":"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998\u20132001","volume":"112","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"2023041908483445000_b39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2023041908483445000_b40","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: An analyis of the CHARM program","volume":"50","author":"Desai","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2023041908483445000_b41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","article-title":"What is the optimal serum potassium level in cardiovascular patients?","volume":"43","author":"Macdonald","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2023041908483445000_b42","first-page":"40","article-title":"Hyperkalemia revisited","volume":"33","author":"Parham","year":"2006","journal-title":"Tex Heart Inst J"},{"key":"2023041908483445000_b43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"},{"key":"2023041908483445000_b44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","article-title":"Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases","volume":"110","author":"Schepkens","year":"2001","journal-title":"Am J Med"},{"key":"2023041908483445000_b45","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1136\/heart.85.4.e8","article-title":"Serious adverse events experienced by patients with chronic heart failure taking spironolactone","volume":"85","author":"Berry","year":"2001","journal-title":"Heart"},{"key":"2023041908483445000_b46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0009-8981(89)90006-5","article-title":"Circadian and seasonal variations of electrolytes in aging humans","volume":"180","author":"Touitou","year":"1989","journal-title":"Clin Chim Acta"},{"key":"2023041908483445000_b47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1378\/chest.116.1.88","article-title":"Exercise-induced rise in arterial potassium in patients with chronic heart failure","volume":"116","author":"Tanabe","year":"1999","journal-title":"Chest"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/86\/1013\/136\/50022457\/postgradmedj-86-136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/86\/1013\/136\/50022457\/postgradmedj-86-136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:13:03Z","timestamp":1681895583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/86\/1013\/136\/7007566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":47,"journal-issue":{"issue":"1013","published-online":{"date-parts":[[2010,3,17]]},"published-print":{"date-parts":[[2010,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2008.072058","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,3]]},"published":{"date-parts":[[2010,3,1]]}}}